Drug-coated Balloon Catheter Market Size, Share, Report 2023-2032
The global drug-coated balloon catheter market size was estimated at around USD 0.66 billion in 2022 and it is projected to hit around USD 1.43 billion by 2032, growing at a CAGR of 8.03% from 2023 to 2032. The drug-coated balloon catheter market in the United States was accounted for USD 216 million in 2022.
Key Pointers
Report Scope of the Drug-coated Balloon Catheter Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 38% |
| Revenue Forecast by 2032 | USD 1.43 billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.03% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Bayer AG; B. Braun SE; Eurocor GmbH; Biosensors International Group; Boston Scientific Corporation; iVascular; Medtronic plc; BIOTRONIK; Caliber Therapeutics; Concept Medical Research |
The drug-coated balloon catheters are also known as drug-eluted balloon catheters which are designed to dilate the stenotic coronary artery and used in the treatment of in-stent restenosis (ISR). The factors such as rise in demand for minimally invasive procedures and innovations in drug-coated/drug-eluting balloons are expected to contribute to growth of the market. The growing older population has had a substantial impact on market share. Additionally, it has been demonstrated that older individuals are more likely to experience health problems, making them more susceptible to diseases like peripheral and cardiovascular abnormalities. Drug-coated/drug-eluting balloons can treat and correct these problems.
Drug-coated/drug-eluting balloons are used by patients to treat coronary atherosclerosis and prevent restenosis. The aforementioned factors are therefore expected to increase consumer demand for drug-coated/drug-eluting balloons.
The COVID-19 pandemic had a major impact on the drug-eluting balloon catheters sector, due to the postponement of peripheral, interventional, along with cardiovascular surgical procedures. The treatment of coronavirus patients was given top priority in many countries to keep the system from becoming overburdened by a large number of cases. Additionally, to prioritize resources for the treatment and care of pandemic patients, hospitals postponed all non-emergency treatments, including catheterization.
Additionally, the prevalence of chronic diseases is increasing, and the desire for minimally invasive surgical procedures is increasing the need for technologically advanced products in healthcare settings. Market growth has spurred recently, thanks to the use of cutting-edge products and surgeries that have enhanced life expectancy as well as sped up diagnostic procedures among the senior demographic base. Market participants are focusing on developing affordable, precise, and efficient drug-eluting/drug-coated balloon catheters to improve medication delivery. Over the projection period, this effort will boost the market expansion of drug-eluting/drug-coated balloon catheters.
Technology development has led to the development of novel items that produce superior results. For instance, Cardiovascular Systems introduced advanced peripheral balloon catheters for complicated lesions in April 2021. Governments also provide funding to companies for research on new technology and safety investigations. This continues to push innovation. For instance, Terumo Corporation stated in April 2022 that the trial using its most recent bobby balloon guide catheter has enrolled its first patient. Thus, it will propel the market growth.
Type Insights
The paclitaxel segment held 97% of the global market share in 2022, accounting for the largest proportion of the market. This is primarily due to the increasing cases of cardiovascular illness. As per the world health organization, cardiovascular disease causes 17.9 million deaths annually, making it the leading cause of death worldwide. By 2030, this number is predicted to increase to over 23.6 million, indicating the urgent need for the advancement of heart-related surgeries. As more medical professionals and healthcare facilities use cutting-edge tools to complete complex interventional procedures. Peripheral vascular balloon catheters enhance the safety of patients throughout surgical treatments by assisting with drug delivery, restricting the growth of vascular smooth muscle cells amid neointimal growth & development, and inhibiting restenosis.
The Sirolimus segmentis expected to grow at a lucrative rate during the forecasted period. As an alternate drug-eluting device to the currently available paclitaxel coat balloon platforms for the management of peripheral artery disease (PAD), sirolimus-coated balloons (SCB) have shown tremendous potential. They have undergone thorough preclinical testing, showing both anti-restenotic efficacy and clinical safety when used to treat coronary artery disease. Thus, it will be propelling the demand for sirolimus among healthcare professionals and further boost the segment growth in coming years.
Product Insights
The peripheral vascular disease segment held 73% of the global market share in 2022, accounting for the largest proportion of the market. Peripheral artery disease (PAD), affects more than 200 million individuals worldwide and is linked to high mortality and morbidity, is addressed in the American Heart Association's 2021 report. The aging of the world's population will probably lead to an increase in PAD cases in the future. Therefore, as per the statistics, the number of PAD is growing more quickly, which ultimately is pushing the market growth.
The coronary artery disease segment is expected to grow at a lucrative rate during the forecasted period. The market is mainly influenced by the rise in coronary artery disease prevalence around the world, rising funding for research and development of devices for the condition, and an increase in comorbid conditions including atherosclerosis and hypertension. Due to the increased risk of chronic diseases among the elderly, the geriatric population is predicted to have a substantial impact on the market under consideration. The percentage of the world's population 60 years of age and older is expected to rise from 12% to 22% between 2015 and 2050, based on the World Health Organization Facts of 2021. 80% of the elderly population worldwide will reside in countries with low or middle incomes by 2050. In comparison to earlier times, the population is aging significantly more quickly, which contributes to the segment's continued expansion.
End-Use Insights
The hospital segment held 41% of the global market share in 2022, accounting for the largest proportion of the market. Due to a greater amount of cardiac & peripheral disease treatments carried out in hospitals. Additionally, the demand for these devices from various settings worldwide is being fueled by suitable compensation provided by these settings as well as the rapid growth of healthcare as well as hospital infrastructure, particularly throughout developing nations. Thus, it will propel the market growth.
Ambulatory surgical centersare expected to grow at a lucrative rate during the forecasted period. The utilization of drug-eluting balloon catheters in ambulatory surgery centers is increasing due to the many benefits they offer. These advantages include shorter operation times, enhanced effectiveness, and better patient outcomes. Therefore, an increasing number of ASCs are opting to use this technology.
Regional Insights
North America accounted for the largest share of the drug-coated balloon catheter market in 2022, with 38%. The significant market share in North America can be attributed to several factors, the availability of various major manufacturers, the launch of new, technologically advanced devices, and favorable reimbursement regulations are all important factors. The American Heart Association estimates that over 500,000 percutaneous coronary procedures, including percutaneous transluminal coronary interventions, are carried out annually in the US. Additionally, rising government expenditure on health care in the U.S. is promoting market expansion.
However, during the anticipated time, the Asia Pacific region is anticipated to have rapid expansion. This can be ascribed to the rise in healthcare expenditure as well as an increase in the incidence of cardiovascular disorders. As per Biomedcentral, cardiovascular disease affects approximately one out of every five individuals in China. In addition, it is anticipated that the demand in the region will be driven by an aging population in countries like China & Japan and rising disposable income. The expansion of the industry in the area is also being aided by the rise of health tourism in emerging countries.
Drug-coated Balloon Catheter Market Segmentations:
By Type
By Product
By End-use
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug-coated Balloon Catheter Market
5.1. COVID-19 Landscape: Drug-coated Balloon Catheter Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug-coated Balloon Catheter Market, By Type
8.1. Drug-coated Balloon Catheter Market, by Type, 2023-2032
8.1.1 Paclitaxel
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Sirolimus
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Drug-coated Balloon Catheter Market, By Product
9.1. Drug-coated Balloon Catheter Market, by Product, 2023-2032
9.1.1. Coronary Artery Disease
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Peripheral Vascular Disease
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Drug-coated Balloon Catheter Market, By End-use
10.1. Drug-coated Balloon Catheter Market, by End-use, 2023-2032
10.1.1. Hospital
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Ambulatory Surgical Centers
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Drug-coated Balloon Catheter Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Product (2020-2032)
11.1.3. Market Revenue and Forecast, by End-use (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-use (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Product (2020-2032)
11.2.3. Market Revenue and Forecast, by End-use (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-use (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Product (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-use (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Product (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-use (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Product (2020-2032)
11.3.3. Market Revenue and Forecast, by End-use (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-use (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Product (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-use (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Product (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-use (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-use (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Product (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-use (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Product (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-use (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.5.3. Market Revenue and Forecast, by End-use (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Product (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-use (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Product (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 12. Company Profiles
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. B. Braun SE.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eurocor GmbH.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Biosensors International Group.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Boston Scientific Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. iVascular
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medtronic plc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. BIOTRONIK
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Caliber Therapeutics.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Concept Medical Research
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers